Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record with results posted

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05614115
Title field or adapter rule
{'original_value': 'Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T01:06:25.769945+00:00
Published At
2026-10-30T00:00:00+00:00
Record Updated At
2026-10-30
Results Posted At
2026-10-30
Source Retrieved At
2026-10-31T01:06:25.053101+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["End-stage Kidney Disease", "Kidney Disease, Chronic", "Dialysis", "Diabetic", "Non-diabetic", "Kidney Dysfunction", "Kidney Failure", "Hemodialysis"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT05614115"
protocolSection.identificationModule.officialTitle
"Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct
{"date": "2026-10-30", "type": "ACTUAL"}

Study condition terms

  • End-stage Kidney Disease (protocolSection.conditionsModule.conditions)
  • Kidney Disease, Chronic (protocolSection.conditionsModule.conditions)
  • Dialysis (protocolSection.conditionsModule.conditions)
  • Diabetic (protocolSection.conditionsModule.conditions)
  • Non-diabetic (protocolSection.conditionsModule.conditions)
  • Kidney Dysfunction (protocolSection.conditionsModule.conditions)
  • Kidney Failure (protocolSection.conditionsModule.conditions)
  • Hemodialysis (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Empagliflozin 10mg', 'Empagliflozin 25mg'], 'description': 'is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.', 'name': 'Empagliflozin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Placebo'], 'description': 'Placebo comparator', 'name': 'Placebo', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Empagliflozin (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.